SCHEMBL2413735

SCHEMBL2413735

CC(C)(Sc1nc(CCOc2ccc(-c3ccc(F)cn3)cc2)cs1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DGAT1 O75907 8/20 0.41
SLC22A12 Q96S37 1/20 0.40
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
PPARA Q07869 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX5AP P20292 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12271460 0.95 RAB9A (0.42) RAB9ANPC1ALDH1A1SMN1; SMN2DGAT1
Hydrochloric Acid SCHEMBL2410755 0.94 RAB9A (0.41) RAB9ANPC1ALDH1A1SMN1; SMN2DGAT1
SCHEMBL2398837 0.91 RAB9A (0.49) RAB9ANPC1ALDH1A1SMN1; SMN2SLC22A12
SCHEMBL2410996 0.89 PPARA (0.42) DGAT1SLC22A12LMNATP53PPARA
SCHEMBL2416137 0.89 DGAT1 (0.41) RAB9ANPC1DGAT1SLC22A12MEN1
SCHEMBL2413830 0.88 RAB9A (0.53) RAB9ASMN1; SMN2POLBPPARA
SCHEMBL12271748 0.87 SLC22A12 (0.41) RAB9ANPC1DGAT1SLC22A12MAPT
Hydrochloric Acid SCHEMBL2410614 0.86 SLC22A12 (0.40) RAB9ANPC1DGAT1SLC22A12MAPT
SCHEMBL2412515 0.85 RAB9A (0.47) RAB9ANPC1ALDH1A1SMN1; SMN2POLB
SCHEMBL2413710 0.85 RAB9A (0.46) RAB9ASMN1; SMN2POLBTP53PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG RAB9A 2891/4885NPC1 271/4885ALDH1A1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.